Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

The Myeloproliferative Neoplasms Channel on VJHemOnc is an independent medical education platform, supported with funding from Takeda (Gold) and Kartos Therapeutics, Inc. (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.

Share this video  

EHA 2020 | PIONEER: avapritinib in patients with indolent systemic mastocytosis

Cem Akin • 10 Jun 2020
EHA 2020
Myeloproliferative Neoplasms Systemic Mastocytosis Avapritinib
PIONEER

Cem Akin MD, PhD, of the University of Michigan, Ann Arbor, MI, discusses the results of PIONEER (NCT03731260), a randomized, double-blind, placebo-controlled, Phase II study of avapritinib in patients with indolent systemic mastocytosis. This interview was recorded via an online conference call with The Video Journal of Hematological Oncology (VJHemOnc).

More from Cem Akin

ddPCR detects KIT D816V mutations with high sensitivity in systemic mastocytosis 1:43
ddPCR detects KIT D816V mutations with high sensitivity in systemic mastocytosis
Cem Akin • 11 Dec 2020
Avapritinib for indolent systemic mastocytosis in the PIONEER trial 5:14
Avapritinib for indolent systemic mastocytosis in the PIONEER trial
Cem Akin • 11 Dec 2020
Mastocytosis: impact of COVID-19 on clinical practice 1:58
Mastocytosis: impact of COVID-19 on clinical practice
Cem Akin • 10 Jun 2020

Related Videos

Targeting CALR mutations in MPNs: a promising novel immunotherapeutic approach 2:14
Targeting CALR mutations in MPNs: a promising novel immunotherapeutic approach
John Mascarenhas • 4 Sep 2025
Ongoing developments with JAK inhibitors in MPNs: JAK2 inhibitors 1:19
Ongoing developments with JAK inhibitors in MPNs: JAK2 inhibitors
John Mascarenhas • 3 Sep 2025
GLP-1 agonists and clinical outcomes in polycythemia vera & MDS 10:06
GLP-1 agonists and clinical outcomes in polycythemia vera & MDS
Asfand Yar Cheema • 5 Sep 2025
The value of fedratinib for the treatment of patients with MF in the second-line setting 1:19
The value of fedratinib for the treatment of patients with MF in the second-line setting
Francesco Passamonti • 5 Sep 2025
The content of VJHemOnc is intended for healthcare professionals